OpenEvidence Raises $210M at $3.5B Valuation – Fastest Growing Medical App
OpenEvidence launches DeepConsult: Revolutionizing Medical Research for Clinicians
Table of Contents
New AI-Powered Tool Offers PhD-Level Research Insights Instantly, Free for U.S. Clinicians
OpenEvidence, the fastest-growing clinical decision support platform in the United States, has announced the launch of DeepConsult, a groundbreaking AI tool designed to provide physicians with complete, PhD-level research reports on complex medical questions.This innovation promises to usher in a new era of medical productivity, offering tireless, agentic research assistance that can uncover insights and unlock new knowledge at an unprecedented scale.
DeepConsult: The Future of Medical Research Assistance
DeepConsult is engineered to function as a highly smart, always-on research assistant for healthcare professionals. Physicians can pose intricate questions and receive detailed, in-depth research reports by the time they return from a short break. This capability is set to transform how clinicians access and utilize medical knowledge,directly impacting patient care and accelerating medical advancements.
While the compute power and cost for each DeepConsult run are over 100 times that of a standard OpenEvidence search, OpenEvidence is committed to its mission of supporting physicians at the point of care. Consequently, DeepConsult will be offered entirely free to all verified U.S. clinicians, irrespective of their institutional affiliation or workplace. This stands in contrast to industry speculation, where similar advanced AI agents are projected to cost tens of thousands of dollars per month.
Strategic Growth and Vision
OpenEvidence plans to leverage its funding to expand strategic content partnerships, further enriching its extensive library of advanced medical knowledge. The company was founded by serial entrepreneur daniel Nadler, the visionary behind Kensho, which was recognized as the most valuable artificial intelligence company of the 2010s before its acquisition by S&P Global for $700 million in 2018. google Ventures was an early investor in Kensho, supporting Nadler during his PhD studies at Harvard University. Nadler’s critically important contributions to global health were further acknowledged in 2025 when he was named to the TIME100 Health list, recognizing the 100 Most Influential People in global health.
OpenEvidence: A Leader in Clinical Decision Support
OpenEvidence has rapidly established itself as the leading clinical decision support platform and the most widely used medical search engine among U.S. clinicians. The platform is trusted by hundreds of thousands of verified physicians, nurses, and othre healthcare professionals. Its widespread adoption is evident across more than 10,000 hospitals and medical centers nationwide, with over 40% of U.S. physicians utilizing it daily for critical clinical decisions.
The platform continues its impressive growth trajectory, with over 65,000 new verified U.S. clinician registrations each month. This rapid adoption rate is unparalleled, with only Google itself having seen technology embraced by clinicians as quickly. OpenEvidence is fundamentally changing how frontline healthcare providers access, evaluate, and apply medical knowledge, with projections indicating that over 100 million Americans will be treated this year by a doctor who has used OpenEvidence.Founded by Daniel Nadler and Zachary Ziegler, OpenEvidence’s core mission is to organize and expand global medical knowledge, thereby redefining evidence-based medicine in real-time. Daniel Nadler’s recognition on the TIME100 Health list in 2025 underscores the profound impact OpenEvidence is having on the healthcare landscape.
SOURCE OpenEvidence